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Inappropriate ICD shocks are associated with increased mortality. They also impair pa-
tients' quality of life, increase hospitalizations, and raise health-care costs. Nearly 80% of
inappropriate ICD shocks are caused by supraventricular tachycardia. Here we report the
case of a patient who received a single-lead dual-chamber sensing ICD for primary pre-
vention of sudden cardiac death and experienced inappropriate ICD shocks. V-A time,
electrogram morphology, and response to antitachycardia pacing suggested atrioventric-
ular nodal reentry tachycardia, which was confirmed in an electrophysiology study.
Inspired by this case, we performed a literature review to discuss mechanisms for
discrimination of supraventricular tachycardia with 1:1 A:V relationship from ventricular
tachycardia with 1:1 retrograde conduction.
Copyright © 2016, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V.
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Implantable cardioverter defibrillator (ICD) use has been
shown to reduce mortality among patients with heart failure
and left ventricular systolic dysfunction [1e6]. However, up toMiami Hospital e East B
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reentrant tachycardia, and AV nodal reentrant tachycardia
(AVNRT) [8]. AF is known to be a common cause of ICD ther-
apies, but the rhythm irregularity and other factors facilitate
fairly accurate discrimination and avoidance of ICD shocks via
device programming [8e10]. At the same time, all SVT entities
with the exception of AF can exist with a 1:1 A-V relationship,
thereby presenting a potential diagnostic challenge.
Discrimination of ventricular tachycardia (VT) from such
arrhythmias is believed to be facilitated by the presence of
dual-chamber detection [11,12]. However, the Centers for
Medicare&Medicaid Services does not reimburse the addition
of an atrial lead for that purpose alone in patientswhohave no
documented SVT prior to device implantation [13], because
there is evidence that SVT-induced ICD shocks can be avoided
just as successfully with a single lead device and optimal de-
vice programming [14e16]. Furthermore, implanting an atrial
lead solely for that purpose adds unnecessary risk to the
procedure, particularly dislodgement, perforation, and
vascular injury [17e19].
It is in that context that the FDA recently approved a novel
ICD lead that enables two-chamber sensing without requiring
a separate atrial lead [20]. Herein we present a patient who
received an ICD using such a lead but nevertheless experi-
enced inappropriate ICD shocks secondary to SVT, consistent
with typical slow-fast AVNRT. This case inspired a literature
review of the discrimination mechanisms designed to differ-
entiate SVT with a 1:1 relationship from ventricular tachy-
cardia (VT) with 1:1 retrograde conduction.Case report
A 57-year-old man with non-ischemic dilated cardiomyop-
athy and an ejection fraction of 20% for several years despite
optimal medical management received an ICD for primary
prevention of sudden cardiac death. The implanted device
employed a single lead with atrial sensing capabilities
(BIOTRONIK Lumax 740 VR-T DX, BIOTRONIK SE & Co KG,
Berlin, Germany). Of note, although he had experienced
palpitations in the past, at the time of device implantation
he had no documented history of tachyarrhythmias. Several
months after the implant, he presented to the electrophys-
iology clinic with recurrent ICD shocks. The patient reported
multiple episodes of palpitations and lightheadedness,
several of which were terminated by ICD shocks. On these
occasions, he was fully conscious when shocked and was
clearly emotionally impacted by the events, as he was now
complaining of fear, anxiety, and a sense of impending
doom. Device interrogation revealed multiple episodes of
tachycardia with a fast ventricular rate (205e225 bpm), a 1:1
V-A relationship, and a V-A time of 50 ms (msec) (Fig. 1). In
several cases, antitachycardia pacing (ATP) was able to
successfully terminate the arrhythmia (Fig. 2). At other
times, despite ventricular capture, ATP was unable to
entrain the tachycardia. In those instances, the tachycardia
persisted after ATP (Fig. 3). On two occasions, the tachy-
cardia fell into the ventricular fibrillation (VF) zone, resulting
in ICD shocks. Table 1 illustrates the device settings at the
time of shock.A diagnosis of AVNRT was strongly suspected on the
retrospective review of the tachycardia episode, based on the
short V-A time, the unchanged ventricular morphology on
intracardiac electrograms, and the response to ATP. The pa-
tient was, therefore, scheduled for an electrophysiology (EP)
study and possible radiofrequency catheter ablation. Mean-
while, in order to avoid further inappropriate shocks while
awaiting the EP study, the VF zone was increased to greater
than 233 bpm. At the EP study, dual AV nodal physiology was
in fact revealed. A narrow complex tachycardia was repro-
ducibly induced with single atrial extra-stimuli (Fig. 4). The
tachycardia had a 1:1 VA relationship, a negative V-A time,
and concentric atrial activation. Entrainment maneuvers
were consistent with typical AVNRT. Slow pathway modifi-
cation was performed, following which tachycardia was no
longer inducible. Post-ablation, the device settings were
returned to the primary prevention settings standard for our
practice. On follow-up device interrogations, there have been
no further episodes of tachycardia. The patient is relieved, but
states that the anxiety caused by this experience has not
completely resolved.Discussion
The aim of this analysis is to highlight potential difficulties in
device discrimination of non-AF SVT from VT and to review
what is known about existing options to prevent inappro-
priate treatment in such cases. The negative consequences of
inappropriate shocks are several-fold. A single inappropriate
shock results in increased mortality, with a hazard-ratio (HR)
of 1.6. The risk further increases with each subsequent shock
until up to a HR of 3.7 after 5 inappropriate shocks [7]. Sig-
nificant behavioral disorders, psychological distress, and a
negative impact on quality of life have also been described
following ICD shocks [21e24]. Furthermore, inappropriate
shocks are pro-arrhythmic and have the potential to cause
malignant ventricular arrhythmias [25,26]. Finally, they also
lead to more frequent clinic visits and hospitalizations, with a
subsequent increase in healthcare costs [27,28].
An observational analysis of 426 patients reported that
13.6% of inappropriate ICD shocks were attributed to AVNRT;
the incidence of AVNRT among ICD recipients was approxi-
mately 3.5% [29]. Current multi-society guidelines give a Class
I indication to catheter ablation for the treatment of symp-
tomatic AVNRT [30]. Catheter ablation targeting the slow
pathway of the AV node has a success rate greater than 95%,
with a risk of heart block requiring pacemaker implantation of
only about 1% [31,32]. In other words, identifying ICD patients
with AVNRT has the potential to reduce or eliminate inap-
propriate shocks, thereby improving patients' quality of life
and possibly even their survival.
The commercially available algorithms used to discrimi-
nate SVT from VT differ depending on whether dual- or
single-chamber sensing is available. In single-chamber
sensing, the most used criteria are electrogram morphology,
interval stability, and suddenness of onset. Both AVNRT and VT
with 1:1 VA conduction typically have a sudden onset and high
interval stability. Therefore, in single-chamber sensing, elec-
trogram morphology is the only criterion capable of
Fig. 1 e A short VA interval (50 msec) is observed in the tachycardia which resulted in ICD shock. A: atrial electrogram; AV:
marker channel; FF: far-field electrogram; V: ventricular electrogram.
Fig. 2 e Antitachycardia pacing with entrainment of the tachycardia, as evidenced by an atrial cycle length (CL) which is (1)
shorter than the tachycardia CL and (2) exactly the same as the ventricular paced CL. In this case, ATP terminates the
tachycardia after entrainment. This response does not differentiate AVNRT fromVTwith 1:1 retrograde conduction (see text
for full explanation). A: atrial electrogram; AV: marker channel; F: far-field electrogram; V: ventricular electrogram.
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such as AVNRT. While this distinction can be easily made in
the setting of “normal” conduction, it is not uncommon for
AVNRT to be associated with rate-related bundle branchblock, thereby removing the usefulness of electrogram
morphology [10].
In dual-chamber sensing, additional criteria for SVT-VT
distinction include comparison of atrial and ventricular rates,
Fig. 3 e Antitachycardia pacing (ATP) with AV dissociation. The shortening of the ventricular cycle length (CL) and the
change in QRS morphology seen on the far-field electrogram confirm ventricular capture. The atrial CL, however, remains
unchanged throughout and after ATP, so entrainment has not occurred. In the setting of ventricular ATP with AV
dissociation, persistence of the tachycardia after ATP is finished is suggestive of an atrial (or sinus) tachycardia or
atrioventricular nodal reentrant tachycardia. This finding excludes atrioventricular reentrant tachycardia and VT with 1:1
VA conduction (see text for full explanation). A: atrial electrogram; AV: marker channel; F: far-field electrogram; V:
ventricular electrogram.
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identified by a ventricular rate > atrial rate [10]. However, up to
20% of patients with VT demonstrate retrograde conduction
and thus have the potential to develop VT with 1:1 retrograde
conduction [33,34]. As in AVNRT, VT with 1:1 VA conduction
presents with AV association and equal atrial and ventricular
rates. Therefore, the distinction between AVNRT and VT with
1:1 VA conduction is highly dependent on timing relationships
between atrial and ventricular electrograms, which is called
P:R pattern analysis [10]. The V-A interval, measured from the
onset of ventricular depolarization to the subsequent earliest
demonstration of atrial activation, is used to characterize theTable 1 e Device parameters at time of shock.
SAV 300e260 msec (60e130 bpm)a
PVAB 75 msec
PVARP 225 msec
PVARP after a PVC 375 msec
VT1 zone 160e179 bpm; monitor only
VT2 zone 180e224 bpm; ATP, shock x 5
VF zone 225 bpm; ATP during charging;
shock x 5
a The SAV decreases from 300 to 260 msec as the patient's heart
rate increases from 60 to 130 bpm. SAV: Sensed AV delay; PVAB:
Post-Ventricular Atrial Blanking; PVARP: Post-Ventricular Atrial
Refractory Period; PVC: Premature Ventricular Contraction.P:R pattern [35]. Atrial and ventricular conduction occur
almost concurrently in AVNRT; the V-A interval is therefore
shorter than in VT [35]. Indeed, the V-A interval is typically
longer than 80 msec in VT with retrograde conduction [36]. In
the patient we present here, therefore, the V-A time of
50 msec is consistent with AVNRT.
While the use of V-A interval is obviously crucial in dis-
tinguishing between AVNRT and VT, it may not be sufficient
for discrimination. Given the importance of atrial sensing in
dual-chamber discriminators and the increased sensitivity
required to detect low-amplitude atrial electrograms, there is
a potential for oversensing of far-field R wave signals and
subsequent overestimation of the atrial rate [10,37]. This
phenomenonmay lead to inappropriate rejection of VT as SVT
or vice versa [10,38e40]. To prevent atrial oversensing of far-
field R waves, some dual-chamber ICDs have a post-
ventricular atrial blanking period, in which the atrial lead is
unable to sense any events for up to 200 ms [10,41]. Under-
sensing of atrial events in the blanking period also has the
potential to cause inappropriate shocks, because the ventric-
ular rate can bemistakenly identified as greater than the atrial
rate [10,14,41]. In fact, in the case here presented, atrial events
were not recognized by the device, as they occurredwithin the
postventricular blanking period. Thus, the ventricular rate
was interpreted as greater than the atrial rate, and VT was
(mistakenly) recognized.
Atrial undersensing (and misclassification of tachycardia
as ventricular rate > atrial rate) is a major limitation of dual-
Fig. 4 e The above narrow complex tachycardia was reproducibly induced following an AH jump during an EP study. The
characteristics of the tachycardia included a 1:1 V-A relationship, a negative V-A time, concentric atrial activation, and
entrainment intervals consistent with typical AVNRT, thereby confirming the suspected diagnosis. Following slow pathway
modification the tachycardia was no longer inducible. I, II, aVF, and V1 ¼ surface electrograms; HRA p ¼ high right atrial
intracardiac electrogram; HBEP, HBEM, and HBED ¼ His intracardiac electrograms (proximal, mid, and distal); CS 9e10, CS
7e8, CS 5e6, CS 3e4, and CS 1e2 ¼ coronary sinus intracardiac electrograms (proximal to distal); RVAp ¼ right ventricular
apical intracardiac electrogram.
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benefit in avoiding inappropriate therapies when compared to
single-chamber devices. In a randomized trial comparing
single to dual-chamber ICDs, 75% of inappropriate therapies
in the dual-chamber group were secondary to atrial sensing
problems, mostly undersensing [15]. Manufacturers have
developed different strategies to overcome the challenges of
setting the post-ventricular atrial blanking period. In Biotronik
SMART algorithm, the blanking period can be adjusted to a
minimal value, in which case sensing of atrial events is not
affected, thereby enabling accurate determination of the atrial
rate and the V-A interval [42]. A similar option is available in
St. Jude Medical and Boston Scientific devices [43]. The Med-
tronic PR Logic and ELA/Sorin algorithms maintain atrial
sensing during the PVAB for the purpose of SVT-VT discrimi-
nation. When a 2:1 AV rhythm is identified, these algorithms
analyze A-V and V-A intervals to reject far-field R waves and
therefore prevent atrial oversensing [43].
Different manufacturers use the various discriminators in
distinct sequences to establish an algorithm for VT/SVT
discrimination. The DX Biotronik ICD system utilizes the
SMART algorithm (Fig. 5), which includes heart rate, interval
stability, A:V association, and P:R pattern analysis. Atrial and
ventricular rates are analyzed first. If the ventricular rate is
faster (Fig. 5, line 1), the rhythm is classified as VT. If the atrial
rate is faster (Fig. 5, line 2), the rhythm is identified as SVT if
either the RR is unstable (suggests variable AV conduction) orthe A/V relationship shows an integral conduction ratio (e.g.,
2:1, 3:1). If the ventricular and atrial rates are equal (Fig. 5, line
3), the system checks for stability and association. If the RR is
stable but the PP is not, there is AV dissociation and VT is
identified. If both RR and PP are stable, the rhythm is classified
as VT if either the PR changes (AV dissociation) or if there is
suddenness of onset. If the RR is unstable, a stable PR (AV
association) indicates SVT, whereas an unstable PR (AV
dissociation) indicates VT [44]. As shown in the bold sequence
of Fig. 5, this algorithm cannot reliably differentiate AVNRT
from VT with retrograde 1:1 conduction, given that both ar-
rhythmias present with equal atrial and ventricular rates,
stable RR and PP intervals (stability), no PR change (AV asso-
ciation), and sudden onset. In this particular sequence, the
SMART system identifies VT. Therefore, the electrophysiolo-
gist should have increased awareness of the possibility of
AVNRT and apply the concepts discussed here to successfully
discriminate this potentially curable arrhythmia.
Unlike the SMART system, St. Jude Medical, Boston Scien-
tific Rhythm ID, and Medtronic PR Logic algorithms utilize
morphology assessments to discriminate SVT from VT [45]. In
Medtronic devices that utilize PR Logic, SVT-VT discrimina-
tion can still occur in the VF zone. PR Logic uses three patterns
of discriminators to identify SVTs (Table 2). Each of these rules
is individually programmable and can be turned off. As in
other dual-chamber sensing algorithms, a ventricular rate
faster than the atrial rate identifies VT. If the rhythm cannot
Fig. 5 e SMART algorithm for tachycardia analysis used in the Biotronik DX single-lead ICD. In our patient, atrial activity
occurred during the post-ventricular atrial blanking period. Thus, the device identified VR > AR (Line 1), and (mistakenly)
called the rhythm VT. In case the device had correctly identified VR¼ AR, the bold sequence illustrates how the rhythm still
would have been called VT. Notice this sequence is unable to discriminate AVNRT from VT with retrograde 1:1 conduction
(see text for full explanation). Modified from: Lori et al. Implantable cardioverter defibrillator system with floating atrial
sensing dipole: A single-center experience. Pacing Clinc Electrophysiol. 2014;37:1265e1273. AR ¼ atrial rate; A/V ≠
N:1¼ conduction ratio not integral; SVT¼ supraventricular tachycardia; VR¼ ventricular rate; VT¼ ventricular tachycardia.
Table 2 e PR Logic algorithm for tachyarrhythmia discrimination (Medtronic Inc.).
SVT rule Device classification
A:V ¼ 1 AND near simultaneous activation of A & V 1:1 SVT
A:V ¼ 1 AND gradual onset AND AV interval consistent with antegrade conduction Sinus tachycardia
Atrial rate > Ventricular rate Irregular VV OR
AV association
AND regular VV
Atrial fibrillation/atrial tachycardia
AV dissociation
AND regular VV
Double tachycardia (coexisting atrial and
ventricular tachyarrhythmias)
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rules can be identified, PR Logic applies morphologic criteria
for discrimination. This is done by checking for concordance
between the unknown tachyarrhythmia and the baseline
ventricular depolarization morphology [45e47].
In addition to the previously mentioned V-A interval, the
response to ATP may also help in discriminating AVNRT from
VT with retrograde 1:1 conduction. Overdrive pacing by ATP
with a cycle length (CL) that is slightly shorter than the
tachycardia CL can lead to one of three responses in AVNRT.
Entrainment occurs when pacing is able to continuously reset
the full tachycardia circuit with each paced beat. In entrain-
ment, the atrial CL exactly matches the paced CL (Fig. 2). AV
dissociation develops when ventricular capture occurs, but the
nodal tachycardia circuit is maintained; in this case, the
ventricular CL matches the paced rhythm, but the atrial CL
remains unchanged from the original tachycardia. Finally,
termination of AVNRT by ATP is also a possibility. Up to 20% of
SVTs can be terminated by ATP [48e50]. Termination and
entrainment also occur in VT; therefore, these responses to
ATP cannot reliably discriminate AVNRT from VT with 1:1 VA
conduction [51,52]. However, maintenance of the sametachycardia CL in the atria after ATP ventricular capture (AV
dissociation; Fig. 3) and after ATP is finished demonstrates that
atrial depolarization during the tachycardia is independent of
ventricular origin. Thus, this finding excludes the possibility
of VT with 1:1 retrograde conduction and atrioventricular
reentrant tachycardia using a usual atrioventricular accessory
pathway. In VT with retrograde 1:1 conduction, when ATP
ventricular capture occurs, the CL in the atria either (1) follows
the CL of the ventricular paced rhythm (if entrainment oc-
curs), or (2) returns to a sinus/atrial paced rhythm if the paced
stimuli are unable to reach the atria. The CL in the atria
cannot, however, remain the same as the tachycardia CL,
given that atrial depolarization arises from a ventricular
stimulus in VT with 1:1 VA conduction.
Importantly, RR intervals falling into the ventricular
fibrillation (VF) zone are not considered for discrimination by
the Biotronik SMART algorithm. At ventricular rates
>200e230 bpm, distinction between VF and SVT is not accu-
rate due to the following: (1) RR intervals in AF can become
more regular [53]; (2) both VF and rapidly conducting AF pre-
sent with AV dissociation [38]; and (3) irregular RR intervals
are also observed in polymorphic VT and VF, which could
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up to 42% and 10% of ICD therapies for ventricular arrhyth-
mias occur at rates > 188 bpmand >250 bpm, respectively, and
thus have the potential to fall under the VF zone [54]. Ricci
et al. showed that 50% of AF-related inappropriate shocks
occur at rates >200 bpm [55]. The concern for VF zone inap-
propriate ICD therapy in SVT is particularly worrisome in
younger patients with rapidly conducting AV nodes, where
the heart rate can reach nearly 250 bpm [29,56]. The patient in
our case had received 2 ICD shocks for SVTwith rates in the VF
zone.Conclusion
Differentiating SVT fromVT in patientswith ICDs is important
in the optimization of clinical outcomes, but this can be
challenging in rhythms with a 1:1 VA relationship. Program-
ming of the post-ventricular atrial blanking period can result
in undersensing of atrial activity (long PVABP) or oversensing
of far-field R waves as atrial activity (short PVABP), which can
misclassify a 1:1 rhythm into ventricular rate > atrial rate, or
vice-versa, respectively. Setting dual-chamber devices to a
minimal blanking period can allow accurate sensing during
the refractory period and precise determination of the V-A
interval, which can be extremely useful in distinguishing
AVNRT (short V-A interval) from VT with 1:1 retrograde con-
duction. The response to ATP may also assist in discrimi-
nating such arrhythmias. Particularly, the persistence of the
tachycardia CL in the atria concomitantly with ATP ventricu-
lar capture (AV dissociation) is highly suggestive of AVNRT.
Catheter ablation is a class I indication for the treatment of
symptomatic AVNRT. Inappropriate shocks due to AVNRT in
patients with ICDs provide further support for this potentially
curative treatment. In this scenario, the procedure has the
added benefit of preventing further inappropriate shocks and
their negative consequences.r e f e r e n c e s
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